Next Phase Newsletter

A venture capital firm based in Paris, France invests in early stage life science companies, seeking to be the first institutional investor in a company. The firm has over €1 billion AUM and is currently investing from a €300M fund raised in 2015. The firm makes seed and venture investments, oftentimes investing in a company’s seed round and later leading the Company’s A round. The firm can allocate €1-10M initially and up to €15M over the life of the investment.

The firm is currently looking for biotech therapeutics, medical devices and industrial biotech. For therapeutics, the firm is agnostic in terms of subsector and invests in small molecules, biologics, cell and gene therapy, etc. The firm is also indication agnostic, but currently most interested in oncology (especially CAR-T assets), CNS/neurology (with a particular interest in rare neuro conditions) and is exploring microbiome technologies, although the firm is less active in this area. The firm will consider products as early as 24-months from IND through to Phase III. For medical devices, the firm seeks paradigm-shifting technologies that can reach a human proof-of-concept stage in a relatively short period of time, and prefers PMA regulatory pathways although is open to other regulatory pathways as well.

The firm prefers to lead or co-lead an investments and generally requires a board seat in its portfolio companies. The firm seeks outstanding entrepreneurial management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare investment firm based in Texas operates as a hybrid of angel and venture capital. The recent fund closed at $21 million in 2014. The firm focuses on making equity investments in the Medical Technology, and Healthcare IT spaces at near commercialization or early commercialization stage. The firm typically invests from $500 K – 1 M per deal, and up to $3 M over the lifetime of a company. The firm plans to make 2-3 investments over the next 6-9 month. The firm is open to consider companies across the US and Canada with a focus on Austin, TX.

The firm is looking for new opportunities in Medical Device, Diagnostics and Healthcare IT, Technology-Enabled Health Services sectors. The firm is open to all classes of medical devices. The firm targets companies with a clear near-term regulatory pathway (such as an FDA 510(k) clearance) and being able to leverage existing distribution channels in order to more efficiently and cost-effectively get to market. The firm typically only considers a medical device or diagnostic that is uniquely differentiated and synergistic with ongoing reform initiatives. The firm does not invest in therapeutics, biotech services or drug development.

The firm will invest in private companies with experienced management team. The firm is most interested in companies that start to generate revenue, but it will also consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm based in New York, NY has launched a health technology fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The fund focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; or provide more meaningful tracking of health metrics for patients (health and wellness analytics).

The firm is an active and engaged investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Hong Kong makes seed and early stage investments across several sectors including the life sciences. The firm typically allocates USD 75K to 500K per company as well as possible continuation into Series A. The firm can invest globally and is actively seeking new investment opportunities.

In the life sciences, the firm is interested in DNA genetic testing. For example, technologies such as pre-natal testing and DNA testing for oncology screening. The firm is also interested in and health & wellness technology for preventive care or management of chronic illness such as diabetes. The firm will focus on startups that have already gained some traction. The firm historically invested in molecular diagnostics and DNA screening.

The firm looks to partner with exceptional entrepreneurs and generally looks to take a board seat post investment, though this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the United Kingdom seeks to invest in companies that need capital within the range of £1m to £10m with a typical investment size at £3 million per company. The firm focuses on investments in life science companies at clinical or growth stage. The firm has a syndicated fund of £100 million, and seeks to make 1-2 new investments within the next year in addition to their current portfolio of 8 active companies. The firm typically leads investments, though will co-invest depending on the opportunity. The firm focuses on UK-based private companies, though is open to companies based in Europe and the U.S.

The firm is currently looking for new opportunities in the Medical Technology and Therapeutics sectors. The firm will also consider diagnostics companies, depending on the opportunity. For therapeutics, the firm will invest in both small molecules and biologics. The firm will consider all classes of medical devices, and prefers to invest in devices with a regulatory pathway. The firm invests in clinical-stage to commercialized products, and prefers clinical-stage technology with a clear path towards revenue.

The firm focuses on private companies and prefers companies with a strong management team and significant growth potential that are able to deliver returns for investors within a 3 to 5-year timetable. The firm looks to take a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the central US is currently in the process of raising its 2nd fund, targeted at $50 million. The firm typically makes equity co-investments in seed and early stage companies ranging from $50,000 to $8 million with most investments in the $250,000 to $1.5 million range. The firm typically makes 6-8 allocations per year, and is open to opportunities throughout the United States and Canada.

The firm is looking for companies in telemedicine, healthcare IT, pathology, diagnostics, bioinformatics, medical devices, and healthcare automation. The firm does not look at pharmaceutical opportunities. The firm is interested in early stage companies from pre-prototype or pre-clinical to clinical stage that have a cost efficient and innovative product with a clear pathway to exit in approximately 3-5 years. The firm is open to consider all indications and types of devices. The firm is not interested in late stage investments into companies that already have a product on the market. The firm focuses on opportunities that focus on patient care improvements, healthcare IT or products that solve critical problems that hospitals, doctors or patients face—and for which the company can receive reimbursement.

The firm is looking for entrepreneur-based management teams with experience who are open to work with them. The firm looks to take a board seat following investment. In addition to capital, the firm is capable of providing strategic mentoring as well as incubation services both locally and remotely in areas of HR, Marketing, Accounting and Software Development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A single family office based in Belgium makes equity investments in life science companies, typically at the Series B stage or later; the firm allocates a total of EUR 3-10 million over the life of an investment. The firm invests in Benelux and neighboring countries.

In the life science sector, the firm invests in therapeutics, diagnostics, medical devices, and healthcare services. For therapeutics companies, Korys only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and microbiomics.

The firm is a hands-on investor that prefers to take a board seat and work closely with management, and therefore prefers to invest in companies located within close travel distance to Brussels. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com